Neuralstem, Inc. (CUR)
-NYSE MKT | Prev Close: | 1.45 |
|---|
| Open: | N/A |
|---|
| Bid: | 1.28 x 200 |
|---|
| Ask: | 1.63 x 1100 |
|---|
| 1y Target Est: | 2.13 |
|---|
| Beta: | 1.29 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 0.42 - 1.96 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 428,102 |
|---|
| Market Cap: | 99.76M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.18 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- A Focus On Stem-Cell Therapy And Regenerative Medicine For 2013at Seeking Alpha(Mon, May 20)
- InPlay: Neuralstem: ALS trial principal investigator presents Phase I data; data shows early stem cell transplantation could slow progression or even improve patient's condition in some forms of ALSBriefing.com(Mon, May 20)
- Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In RomaniaPR Newswire(Mon, May 20)
- SmithOnStocks Opines On Stocks: May 19th Editionat Seeking Alpha(Sun, May 19)
- Cloning: A Stem Cell Revolution?at Motley Fool(Sun, May 19)
- NEURALSTEM, INC. FinancialsEDGAR Online Financials(Fri, May 17)
- Smaller Companies With Potential For Big Returnsat Seeking Alpha(Thu, May 16)
- Neuralstem: Update On ALS Trial Could Be A Catalyst For The Stockat Seeking Alpha(Thu, May 16)
- Neuralstem CEO, Richard Garr, To Present At Annual World Stem Cells And Regenerative Medicine Congress In LondonPR Newswire(Thu, May 16)
- Neuralstem Rounding Second With Phase II ALS Trialat Seeking Alpha(Thu, May 16)
- Neuralstem Principal Investigator, Dr. Eva Feldman, Presents Phase I ALS Trial Data At The Romanian Neurological Society CongressPR Newswire(Mon, May 13)
- SmithOnStocks Opines On Recent Biotech Newsat Seeking Alpha(Mon, May 13)
- Neuralstem Reports First Quarter Financial Results And Provides Business And Clinical UpdatePR Newswire(Fri, May 10)
- NEURALSTEM, INC. Files SEC form 8-K, Results of Operations and Financial ConditionEDGAR Online(Fri, May 10)
- NEURALSTEM, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Fri, May 10)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 281.83 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.18 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.05 |
|---|
| Mean Recommendation*: | 3.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Neuralstem, Inc., a biopharmaceutical company, focuses on the development and commercialization of treatments for central nervous system disease based on human neural stem cells and the use of small molecule compounds.
View More 
0.12%